drugset / Trial / NCT01380769
A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare median overall survival of patients with advanced non-small cell lung cancer (NSCLC) treated with CRLX101 to patients treated with best supportive care (BSC).
Timeline
- Start
- 2011-06
- Primary completion
- 2013-02
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DAVAMOTECAN PEGADEXAMER | Other / unclassified | 15 mg/m2 | Intravenous |